STAT6 and non-small cell lung carcinoma: Clinical pathological analyses reveal that approximately 54% of non-small cell lung cancers exhibit high STAT6 expression levels, with this abnormal expression pattern being particularly prominent in immune cell populations infiltrating the pulmonary interstitium (Pastuszak-Lewandoska et al., 2017).